2018 Annual Meeting | N1 - Neuroscience in the Clinic: Autism Myth Busters

Date Sunday 04/22/18

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Neuroscience in the Clinic Session

Director(s) Shafali Jeste, MD, FAAN, Sarah J. Spence, MD, PhD

Topic(s) Child Neurology and Developmental Neurology

Learning Objectives Participants should become familiar with insights on early signs of ASD gained from studies of infants at risk for ASD; the definition of a biomarker and an understanding of the types of biomarkers investigated in ASD; challenges around clinical trial design and implementation in ASD; evidence around pharmacological interventions for ASD and updates from clinical drug trials; and updates on autism genetics, from recommended diagnostic practices to implications for management.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
03:30 PM - 03:45 PM	Speaker	Clinical Vignette: Autism Spectrum Disorders Sarah J. Spence, MD, PhD
03:30 PM - 05:30 PM	Abstract	001 - The Broader Autism Phenotype in Tuberous Sclerosis Complex Jamie K. Capal, MD
03:30 PM - 05:30 PM	Abstract	002 - Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report Andrew W. Zimmerman, MD, FAAN
03:30 PM - 05:30 PM	Abstract	003 - Multi-Gene Panels vs. Diagnostic Exome Sequencing: A Comparison of Genetic Testing Options for Neurodevelopmental Disorders Jing Wang, MD
03:45 PM - 04:00 PM	Speaker	Biomarkers of ASD: From Screening to Clinical Stratification to Quantitative Outcomes Shafali Jeste, MD, FAAN
04:00 PM - 04:10 PM	Speaker	N1.001: The Broader Autism Phenotype in Tuberous Sclerosis Complex Jamie K. Capal, MD
04:10 PM - 04:25 PM	Speaker	Clinical Trials and Treatments in ASD: What Works and Why Trials Fail
04:25 PM - 04:35 PM	Speaker	N1.002: Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report Andrew W. Zimmerman, MD, FAAN
04:35 PM - 04:50 PM	Speaker	Updates in Autism Genetics: Clinical and Scientific Implications for Precision Medicine Daniel H. Geschwind, MD, PhD
04:50 PM - 05:00 PM	Speaker	N1.003: Multi-Gene Panels vs. Diagnostic Exome Sequencing: A Comparison of Genetic Testing Options for Neurodevelopmental Disorders Jing Wang, MD
05:00 PM - 05:30 PM	Q&A	Panel Discussion

Faculty Disclosures
Shafali Jeste, MD, FAAN	Dr. Jeste has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche Pharmaceuticals. Dr. Jeste has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals. Dr. Jeste has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN Continuum. The institution of Dr. Jeste has received research support from NIH. The institution of Dr. Jeste has received research support from DoD. The institution of Dr. Jeste has received research support from Dup15q Alliance.
Sarah J. Spence, MD, PhD	Dr. Spence has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for dup15qalliance. The institution of Dr. Spence has received research support from Hoffman La Roche. The institution of Dr. Spence has received research support from NIH.
	No disclosure on file
Jamie K. Capal, MD	Dr. Capal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CTI Clinical Trials. Dr. Capal has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Intellectual Disability Research. The institution of Dr. Capal has received research support from NIH. The institution of Dr. Capal has received research support from Roche . The institution of Dr. Capal has received research support from Ionis.
Andrew W. Zimmerman, MD, FAAN	No disclosure on file
Jing Wang, MD	No disclosure on file
Daniel H. Geschwind, MD, PhD	Dr. Geschwind has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Ovid Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axial Biotherapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Falcon Computing. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier-Biological Psychiatry. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NYAS. Dr. Geschwind has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Covington& Burling LLP. Dr. Geschwind has stock in none related to talk. The institution of Dr. Geschwind has received research support from CurePSP. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from Rainwater Charitable Foundation. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from The Simons Foundation. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS/NIA. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NIH/NINDS. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from U of Virginia and NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from NIH/NHGRI. The institution of Dr. Geschwind has received research support from NIH/NIMH. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care.
Heather Newman	No disclosure on file
Susan L. Connors, MD	No disclosure on file
Darcy Krueger, MD	Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NobelPharma USA. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for RegenxBio. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharmaceuticals. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Greenwich Biosciences. The institution of Dr. Krueger has received research support from Greenwich Bioscience. The institution of Dr. Krueger has received research support from Marinus Pharmaceuticals. The institution of Dr. Krueger has received research support from National Institutes of Health. The institution of Dr. Krueger has received research support from Food and Drug Administration. The institution of Dr. Krueger has received research support from TSC Alliance.
Mustafa Sahin, MD, PhD	Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regenxbio . Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Centene. Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for PTEN Research. Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Sahin has received research support from NIH. The institution of Dr. Sahin has received research support from Tuberous Sclerosis Alliance. The institution of Dr. Sahin has received research support from Charities Aid Foundation. The institution of Dr. Sahin has received research support from Simons Foundation Autism Research Initiative. The institution of Dr. Sahin has received research support from Aucta Pharmaceuticals . The institution of Dr. Sahin has received research support from Loulou Foundation.